No Data
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ
Express News | Abbvie Inc. : Morgan Stanley Raises Target Price to $218.00 From $211.00
Morgan Stanley Adjusts Price Target on AbbVie to $218 From $211, Maintains Overweight Rating
The Yen Carry Trade Is a Distraction. Stocks Have More Fundamental Problems, Says Morgan Stanley's Wilson
Robert Bruce Amplifies Stake in AbbVie Inc, Highlighting Strategic Portfolio Adjustments in Q2 2024
10baggerbamm : big day Wednesday hopefully we see I knock the cover off the ball moment exceed whisper number exceed revenue number and exceed forward guidance expectations if we can achieve that it's over 100 bucks